StockData

Autolus Therapeutics vs Immunocore

AUTL and IMCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AUTL and IMCR compare

Immunocore is the larger company, worth 5.0 times as much as Autolus Therapeutics ($1.5B against $311M).

Autolus Therapeutics grew revenue faster over the last twelve months (169% versus 13.1% for Immunocore).

Immunocore keeps more of each dollar of sales as profit, with a net margin of −7.5% compared with −186% at Autolus Therapeutics.

Immunocore scores higher on the StockData Score (7 against 4 for Autolus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAUTLIMCR
Size and price
Market cap$311M$1.5B
Share price$1.17$29.94
Change, 1 year−14.0%−15.2%
Change, 5 years−81.2%−21.4%
Beta (5Y)1.840.69
Employees754524
StockData Score
Total score47 (better)
Valuation score01 (better)
Growth score3 (better)2
Performance score03 (better)
Health score11
Dividend score00
Valuation
P/S2.3× (better)3.6×
P/B11.4×3.7× (better)
FCF yield−57.9%−1.2% (better)
Fair value–$31.07
Margin of safety–3.6%
Growth
Revenue growth (TTM)169% (better)13.1%
Profitability
Gross margin35.8%98.9% (better)
Operating margin−160%−6.8% (better)
Net margin−186%−7.5% (better)
FCF margin−131%−4.2% (better)
Return on equity−175%−7.9% (better)
Financial health
Interest coverage−4.8×−2.4× (better)
Current ratio3.724.62 (better)
Altman Z-score−4.281.45 (better)
Piotroski F-score23 (better)
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Shareholder yield0.00%0.00%
Ownership
Held by institutions49.7%102%
Held by insiders24.6%15.5%
Insider net buying, 12 months−$15.7K (better)−$1.9M

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.